Browsing Tag
Greenstone Biosciences
2 posts
NIH backs Greenstone Biosciences iPSC and AI programme for Duchenne cardiomyopathy
Greenstone Biosciences has secured a National Institutes of Health R61 award to discover potential treatments for cardiac fibrosis and dilated cardiomyopathy in Duchenne muscular dystrophy, extending its patient-derived stem-cell drug discovery strategy into one of the disease’s most consequential complications.
Greenstone Biosciences wins NHLBI R61 award to identify small-molecule treatments for DMD heart disease
Greenstone Biosciences has secured a $625,968 National Heart, Lung, and Blood Institute (NHLBI) R61 grant to combine patient-derived stem cells, proteomics and artificial intelligence in the search for small-molecule treatments for cardiac fibrosis in Duchenne muscular dystrophy (DMD). The award validates the company’s human-cell-based discovery platform, but target selection, compound validation and progression into the programme’s R33 phase remain critical tests.